DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Fox EJ, Arnold DJ, Cohen JA.
Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II with most patients free from treatment for 5 years.
Poster session presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 7–10, 2015; Barcelona, Spain
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.